US Patent

US9789057 — Pharmaceutical delivery system

Method of Use · Assigned to Perrigo Pharma International Designated Activity Co · Expires 2026-12-02 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical formulation for treating vaginal conditions in humans with a modified release dosage form that provides extended release of an anti-infective agent.

USPTO Abstract

A pharmaceutical formulation to treat vaginal conditions in a human patient comprises: at least one active agent; a modified release dosage form which provides extended release of the anti-infective agent upon vaginal administration to the patient; and wherein the formulation, when containing a total dose of the anti-infective agent of about 25 μg to about 500 mg based on the active agent will produce a plasma concentration versus time curve (ng/mL versus hours) having an area under the curve (AUC) of less than about 600 ng/mL·hr.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-137 — Cleocin T

Patent Metadata

Patent number
US9789057
Jurisdiction
US
Classification
Method of Use
Expires
2026-12-02
Drug substance claim
No
Drug product claim
Yes
Assignee
Perrigo Pharma International Designated Activity Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.